EverSource Wealth Advisors’s Design Therapeutics DSGN Stock Holding History

EverSource Wealth Advisors’s Portfolio DSGN Stock Details DSGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$362	Buy	25 +15	+150%	+$187	﹤0.01%	4177
2026 Q1	$107	Buy	10 +7	+233%	+$71	﹤0.01%	4262
2025 Q4	$28	Sell	3 -232	-99%	-$1.82K	﹤0.01%	4208
2025 Q3	$1.77K	Hold	235	–	–	﹤0.01%	3559
2025 Q2	$792	Buy	235 +204	+658%	+$763	﹤0.01%	3789
2025 Q1	$120	Buy	+31	New	+$148	﹤0.01%	3795
2023 Q2	–	Sell	-79	Closed	-$456	–	2519
2023 Q1	$456	Buy	+79	New	+$591	﹤0.01%	2244

Other funds holding DSGN

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return

Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return

AlphaCentric Advisors San Juan, Puerto Rico $118M AUM

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

EverSource Wealth Advisors's DSGN Position: Q2 2026 in Review

EverSource Wealth Advisors increased its Design Therapeutics (DSGN) stake by 150% in Q2 2026, buying an estimated $187 and bringing the position to 25 shares worth $362. The position accounts for ﹤0.01% of the portfolio, ranked #4177.

EverSource Wealth Advisors first reported a position in DSGN in Q1 2023 and has held it in 7 quarters since. The position peaked at $1.77K in Q3 2025. 23 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

EverSource Wealth Advisors held 25 shares of Design Therapeutics worth $362 as of Q2 2026.
EverSource Wealth Advisors bought 15 Design Therapeutics shares in Q2 2026, an estimated $187.
Design Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #4177 holding.
EverSource Wealth Advisors first reported a position in Design Therapeutics in Q1 2023 and has held it in 7 quarters since.
EverSource Wealth Advisors's Design Therapeutics position peaked at $1.77K in Q3 2025.
23 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.